Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients.

被引：2
|
作者：
Scher, Howard I.
Graf, Ryon
Louw, Jessica
Jendrisak, Adam
Johnson, Ann
Greene, Stephanie
Rodriguez, Angel
Schreiber, Nicole A.
McLaughlin, Brigit
Dugan, Lyndsey
Fleisher, Martin
Lee, Jerry
Wang, Yipeng
Marrinucci, Dena C.
Landers, Mark
Dittamore, Ryan Vance
机构：
[1] Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Epic Sci Inc, San Diego, CA USA
[4] Epic Sci, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 02期
关键词：
D O I：
10.1200/jco.2016.34.2_suppl.163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
163
引用
收藏
页数：1
相关论文
共 2 条
  • [1] CTC phenotype classifier to identify mCRPC patients (pts) with high genomic instability CTCs and to predict failure of androgen ecreptor signaling (AR Tx) and taxane (T) systemic therapies.
    Scher, Howard I.
    Jendrisak, Adam
    Graf, Ryon
    Schreiber, Nicole A.
    McLaughlin, Brigit
    Greene, Stephanie
    Rodriguez, Angel
    Louw, Jessica
    Dugan, Lyndsey
    Leitz, Laura
    Fleisher, Martin
    Lee, Jerry
    Wang, Yipeng
    Landers, Mark Andrew
    Dittamore, Ryan Vance
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Presence of AR-V7 splice variant or AR C terminal loss in the CTCs of mCRPC patients identifies patients with improved PSA response with taxanes over androgen receptor signaling directed therapies (ARS Rx)
    Scher, H. I.
    Kelvin, J.
    Lu, D.
    Louw, J.
    Packer, D.
    Bambury, R.
    Rathkopf, D.
    Schreiber, N.
    Brennan, R.
    Prigozhina, N.
    Brown, D.
    Jendrisak, A.
    Dugan, L.
    Landers, M.
    Lee, F.
    Fleisher, M.
    Marrinucci, D.
    Dittamore, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S93 - S93
1